Follow Slashdot blog updates by subscribing to our blog RSS feed

 



Forgot your password?
typodupeerror

Comment: Re:The research is very interesting (Score 3, Interesting) 61

by toppavak (#49188457) Attached to: Inside the Weird World of 3D Printed Body Parts
Printed parts are still by far inferior to more conventionally produced alternatives. For organs with 3D architecture, by far the most successful approaches have been to basically seed the relevant cell types in layers on a gel or degradable fiber based scaffold. Anthony Atala's group at Wake Forest (no association, just a fan of their work) has made replacement urethras and bladders among many others that have actually been implanted in patients. I believe the bladder work is currently in a phase II clinical trial on its way to becoming more widely available. Sangeeta Bhatia's group has done amazing work on liver tissue, although their focus has been on laboratory samples for drug testing rather than implantation for the time being. They actually do use a 3D printing approach to their work but only to build a sugar-based scaffold that can dissolve away and leave space for blood vessels to be engineered. The tissue itself is just dumped onto the scaffold in a gel slurry and organizes itself.

I think 3D printing tissues is a rather short-sighted approach to assembling structures whose function and shape is self-organized. The most successful approaches thus far (in terms of having products on the market or organs in people) have been strategies that rely on the intrinsic self-organization of tissues. Even more complex structures such as the colonic epithelium can be generated this way.

Comment: Re:Real Unix makes the difference. (Score 3, Informative) 308

by toppavak (#45654553) Attached to: Google's Plan To Kill the Corporate Network

Our entire development team uses Macbooks - and of 12 users, only two of them run OSX. One of them is even geeky enough to paste a Tux logo over the light-up Apple logo.

The last time I visited Google HQ (about 5 years ago) the most common setup I saw was Thinkpads running Linux with Macbooks running Linux in a close second.

Comment: Re: It's true. (Score 1) 214

by toppavak (#45355615) Attached to: What Apple Does and Doesn't Know About You
Not in the slightest. I'm one of (seemingly many) people who seem to believe that the payment Google offers in exchange for access to my personal information is quite fair. Just because you don't doesn't mean that other people are somehow ignorant for not having realized what "the game" is, it just means that they have slightly different ideas of what different types of privacy mean to them, which aspects of their privacy they are willing to put a price on and what that price might be.

Comment: Re:Simple (Score 1) 189

by toppavak (#45250531) Attached to: Why Johnny Can't Speak: a Cost of Paywalled Research
Which is why it's fairly costly to publish in the Public Library of Science (PLoS) with publication fees ranging from $1,350 to $2,900. Fortunately most grants allow you to use those funds to pay the submission fees and many universities (at least in the US) have programs that can help support the cost as well.

Comment: Re:Simple (Score 2) 189

by toppavak (#45250517) Attached to: Why Johnny Can't Speak: a Cost of Paywalled Research
Generally yes, although the specific restrictions may vary. From the link (PMC = PubMed Central):

The PMC Open Access Subset some or all openaccess content is a part of the total collection of articles in PMC. Articles in the PMC Open Access Subset are still protected by copyright, but are made available under a Creative Commons or similar license that generally allows more liberal redistribution and reuse than a traditional copyrighted work. Note, however, that the license terms are not identical for all of the articles in this subset. Please refer to the license statement in each article for specific terms of use. We also provide a search-by-license feature, described below, which enables finding articles with specific reuse rights.

Comment: Re: Ends? (Score 3, Insightful) 999

by toppavak (#45151379) Attached to: US Government Shutdown Ends
Right, this has nothing to do with the fact that a no strings attached version of the bill had enough Republican votes in the house to pass from the get go but the republican caucus in the house changed the parliamentary rules so only the majority leader could bring the bill to vote, ie boehner, who proceeded to refuse to do so to begin this whole charade of brinkmanship to begin with. Citation: http://touch.baltimoresun.com/#section/-1/article/p2p-77802818/

Comment: Re:Applications (Score 4, Interesting) 170

by toppavak (#44700883) Attached to: Mini-Brains Grown In the Lab
Exactly, in my lab we work primarily on bone and colon tissue (although generated from adult stem or induced pluripotent stem cells). It would not be exaggerating to call these technologies the next generation of medical research. There are tons of genetic and developmental disorders that are either too rare to study readily in vivo or just impossible to study in-vitro. We're nearing the point where we can start with IPSC's either engineered to carry mutations of interest or derived directly from patients carrying these mutations and turn them into all sorts of tissues: liver, colon, neural, vascular, muscular, etc. In many cases it's not even necessary to get to the stage of organoids, simply having true human tissue with the right pathophysiology will be a tremendous boon to in-vitro drug screening and discovery and far more relevant than animal models.

Comment: Re:Just keep in mind the tradeoff (Score 1) 556

by toppavak (#39342379) Attached to: Indian Gov't Uses Special Powers To Slash Cancer Drug Price By 97%
A valid point, perhaps one mitigating bit of information worth noting is that compulsory licensing does not mean that the generic manufacturer can violate the patent. Under TRIPS (the international treaty governing intellectual property rights) what the Indian government has done is to deem the asking cost of a drug combined with the asking cost or unwillingness of the manufacturer to license the drug to generic manufacturers to be damaging to public health (I forget the precise phrasing used). As a consequence they've issued a "mandatory license" by which the generic manufacturer can pay Bayer a licensing fee established as reasonable by the government exercising its right to compulsory licensing, essentially granting a license to the patent it issued to Bayer to generics manufacturers for domestic production and consumption in order to ensure access to the drug. Hence the 6% licensing fee on revenues (not profit) referenced in the article. Arguably, Bayer stands to make that money for free considering the vast majority of the consumption of that drug will be by patients who could not have afforded the treatment previously.

Certainly there are potential negative consequences of such an action, but the calculus of such a decision would involve weighing these potential future costs of "decreased innovation due to perceived risk of diminished monopoly" against the very immediate human cost of not having access to treatment. In this case it seems that the government of India decided that the immediate cost outweighed the potential future cost.

Comment: Re:Common Sense, anyone? (Score 5, Interesting) 788

by toppavak (#36946174) Attached to: Re: the debt deal reached Sunday night ...

Many doctors are quitting the profession because of 0bamacare.

Citation please? Most of my doctor friends (I work in a science department at a medical school) are actually staunchly pro-single payer / nationalized health. The data seems to back that up as well.
The original article has some more detailed information.

Humanity has the stars in its future, and that future is too important to be lost under the burden of juvenile folly and ignorant superstition. - Isaac Asimov

Working...